(L to R) Usha Chakravarthy, MBBS, PhD; Allen Ho, MD, FACS, FASRS; and Frank Holz, MD, FEBO, FARVO.

WATERTOWN, Mass.—EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company that develops therapeutics to improve the lives of patients with serious retinal diseases, has announced the appointment of leading global ophthalmologists to its scientific advisory board (SAB), co-chaired by Carl Regillo, MD, FACS, chief of the retina service at Wills Eye Hospital, and Charles Wykoff, MD, PhD, director of research of Retina Consultants of Texas. The SAB additions include Usha Chakravarthy, MBBS, PhD; Allen Ho, MD, FACS, FASRS; and Frank Holz, MD, FEBO, FARVO. These three retinal specialists will support advancement of the company’s global clinical strategy ahead of the anticipated initiation of its Phase 3 pivotal trials in wet age-related macular degeneration in the second half of this year.

Additionally, the company announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the trade name Duravyu (vorolanib intravitreal insert) for the company’s lead product candidate, EYP-1901.

“We are honored to add these prominent leaders of the retina community to our SAB as we approach the topline data readout of the Phase 2 Pavia trial for non-proliferative diabetic retinopathy later this quarter, and as we prepare for the initiation of our global Phase 3 program in the second half of 2024,” said Ramiro Ribeiro, MD, PhD, chief medical officer of EyePoint. “The SAB’s strategic counsel, global expertise, and scientific knowledge will be incredibly valuable during this critical time in EyePoint’s growth and expansion. The caliber of our expanded SAB speaks to the quality and potential of our programs, and I look forward to this collaboration to further expand our product candidates and to bring novel treatment options to patients globally.”

 
 
“Following EyePoint’s strong and convincing Phase 2 DAVIO 2 data for DURAVYU in wet AMD, I am delighted to have these distinguished leaders on the cutting edge of ophthalmic research join the SAB,” said Dr. Regillo. “I look forward to collaborating with Dr. Wykoff in his expanded role, as well as the renowned members of the SAB and EyePoint management team, as we work to improve the lives of patients with serious retinal diseases.”